论文部分内容阅读
目的探讨左卡尼汀在血液透析患者中的应用效果。方法回顾分析40例患者的临床资料。结果治疗组在应用左卡尼汀4个月后体力、精神状态明显改善,血红蛋白由(63.5±9.0)g/L上升至(98.0±6.0)g/L,对照组血红蛋白由(64.0±8.5)g/L上升至(84.2±8.0)g/L,两组血红蛋白上升比较,治疗组优于对照组(P<0.05)。结论左卡尼汀能够改善血脂,促进贫血的纠正,改善维持性血液透析患者的心功能,减少患者透析相关性低血压、心律失常及心绞痛等的发生,值得临床应用。
Objective To investigate the effect of levocarnitine in hemodialysis patients. Methods The clinical data of 40 patients were retrospectively analyzed. Results After 4 months of treatment, the physical and mental status of the patients in the treatment group were significantly improved, the hemoglobin increased from (63.5 ± 9.0) g / L to (98.0 ± 6.0) g / L, and the hemoglobin in the control group increased from (64.0 ± 8.5) g / L increased to (84.2 ± 8.0) g / L, hemoglobin increased in both groups, the treatment group was better than the control group (P <0.05). Conclusion L-carnitine can improve blood lipid, promote the correction of anemia, improve the cardiac function of maintenance hemodialysis patients, reduce dialysis-related hypotension, arrhythmia and angina, which is worthy of clinical application.